Literature DB >> 2921843

Correlation of caffeine elimination and Child's classification in liver cirrhosis.

A Holstege1, M Staiger, K Haag, W Gerok.   

Abstract

Apparent pharmacokinetic parameters of caffeine elimination from the circulation were determined in 27 patients with histologically confirmed liver cirrhosis, 8 patients with miscellaneous liver disease, and 8 patients with other than liver disease. The usefullness of this quantitative test to assess the severity of liver cirrhosis was compared to the Child-Turcotte or Child-Pugh classification score as well as to the galactose elimination capacity of these patients. Using reversed-phase high pressure liquid chromatography caffeine, paraxanthine, theophylline, and theobromine were analysed in blood plasma collected before and after an oral dose of caffeine. Compared to apparent caffeine pharmacokinetics in patients with normal livers or miscellaneous liver disease, cirrhosis was characterized by a statistically significant reduction in apparent caffeine clearance and prolongation in half-life. The reduced apparent plasma disappearance rate of caffeine in cirrhotics was related to the retarded formation of paraxanthine which was the main metabolite of caffeine in blood plasma both in the absence or presence of liver disease. The apparent caffeine clearance in cirrhosis decreased with increasing Child-Turcotte classification score: Child's class A patients differed significantly from Child's class B or Child's class C patients, whereas the difference between Child's class B and C patients did not reach statistical significance (Wilcoxon's rank test). In addition there was a strong correlation between the Child-Pugh classification score and apparent caffeine clearance (P less than 0.001). However, no correlation existed between Child's classification and galactose elimination capacity. Our data emphasize the value of the Child-Turcotte or Child-Pugh classification in assessing the severity of liver cirrhosis in a simpler and less time-consuming way than using quantitative liver function tests.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921843     DOI: 10.1007/BF01736528

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  41 in total

1.  Assessment of prognosis in advanced liver disease: to score or to measure, that's the question.

Authors:  J Bircher
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

2.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

3.  Overnight salivary caffeine clearance: a liver function test suitable for routine use.

Authors:  G Jost; A Wahlländer; U von Mandach; R Preisig
Journal:  Hepatology       Date:  1987 Mar-Apr       Impact factor: 17.425

4.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

6.  Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease.

Authors:  A Wahlländer; E Renner; R Preisig
Journal:  Scand J Gastroenterol       Date:  1985-11       Impact factor: 2.423

7.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

8.  The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

Authors:  A N Kotake; D A Schoeller; G H Lambert; A L Baker; D D Schaffer; H Josephs
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

9.  Prognostic value of the aminopyrine breath test in cirrhotic patients.

Authors:  J P Villeneuve; C Infante-Rivard; M Ampelas; G Pomier-Layrargues; P M Huet; D Marleau
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

10.  Caffeine elimination: a test of liver function.

Authors:  T Wang; G Kleber; F Stellaard; G Paumgartner
Journal:  Klin Wochenschr       Date:  1985-11-04
View more
  7 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  The role of salivary caffeine clearance in the diagnosis of chronic liver disease.

Authors:  Anurag Tripathi; Brijesh Tiwari; Ranjit Patil; Vikram Khanna; Vandana Singh
Journal:  J Oral Biol Craniofac Res       Date:  2015-01-23

Review 3.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 4.  Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.

Authors:  Katherine Schoen; Tian Yu; Chris Stockmann; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

5.  Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.

Authors:  Giovanni Tarantino; Paolo Conca; Domenico Capone; Antonio Gentile; Giuliano Polichetti; Vincenzo Basile
Journal:  Eur J Clin Pharmacol       Date:  2006-07-14       Impact factor: 2.953

6.  Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole.

Authors:  Carina Centerholt; Marianne Ekblom; Tomas Odergren; Olof Borgå; Gabriela Popescu; Karl-Heinz Molz; Andrea Couturier; Angelika Weil
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

Review 7.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.